IDH1 and glioblastoma: In addition to mutations in the gene encoding for isocitrate dehydrogenase enzyme 1/2 (IDH1/2), which identify different GBM subgroups, genetically altered RTKs and their downstream effectors are likely the most abundant targetable driver mutations in GBM.